Immune surveillance and immunotherapy: Lessons from carbohydrate mimotopes

Vaccine

Volumn 27, Issue 25-26, 2009, Pages 3405-3415

  Pashov, Anastas ^a   Monzavi Karbassi, Behjatolah ^a   Kieber Emmons, Thomas ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Cancer immunotherapy; Carbohydrate mimotopes

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CARBOHYDRATE; EPITOPE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN M ANTIBODY; MELANOMA VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; POLYVALENT ALLOGENEIC CELL VACCINE; TRYPTOPHYLARGINYLTYROSYLTHREONYLALANYLPROLYLVALYLHISTIDYLLEUCYL GLYCYLASPARTYLGLYCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIBODY TITER; ARTICLE; AUTOIMMUNITY; BACTEREMIA; BACTERIAL INFECTION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARCINOGENESIS; CELL ACTIVITY; CLINICAL TRIAL; CORRELATIONAL STUDY; CYTOTOXICITY; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; INNATE IMMUNITY; INTROSPECTION; MELANOMA; MENINGOCOCCOSIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STAPHYLOCOCCAL PNEUMONIA;

ANIMALS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CANCER VACCINES; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; KILLER CELLS, NATURAL; NEOPLASMS; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 67349134633     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.074     Document Type: Article

References (145)

1. Pashov A., Monzavi-Karbassi B., Chow M., Cannon M., and Kieber-Emmons T. Immune surveillance as a rationale for immunotherapy?. Hum Vaccin 3 5 (2007) 224-228
2. Dabelsteen E. Cell surface carbohydrates as prognostic markers in human carcinomas. J Pathol 179 4 (1996) 358-369
3. Nakagoe T., Sawai T., Tuji T., Jibiki M., Nanashima A., Yamaguchi H., et al. Prognostic value of expression of sialosyl-Tn antigen in colorectal carcinoma and transitional mucosa. Digest Dis Sci 47 2 (2002) 322-330
4. Slovin S.F., Keding S.J., and Ragupathi G. Carbohydrate vaccines as immunotherapy for cancer. Immunol Cell Biol 83 4 (2005) 418-428
5. Takahashi T., Johnson T.D., Nishinaka Y., Morton D.L., and Irie R.F. IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J Invest Dermatol 112 2 (1999) 205-209
6. Hsueh E.C., Gupta R.K., Qi K., and Morton D.L. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 16 9 (1998) 2913-2920
7. Vollmers H.P., and Brandlein S. The "early birds": natural IgM antibodies and immune surveillance. Histol Histopathol 20 3 (2005) 927-937
8. Vuist W.M., Van Schaik I.N., Van Lint M., and Brand A. The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids. J Clin Immunol 17 4 (1997) 301-310
9. Erttmann R. Treatment of neuroblastoma with human natural antibodies. Autoimmun Rev 7 6 (2008) 496-500 Epub 2008 Apr 15
10. Ravindranath M.H., Muthugounder S., Presser N., Ye X., Brosman S., and Morton D.L. Endogenous immune response to gangliosides in patients with confined prostate cancer. Int J Cancer 116 3 (2005) 368-377
11. Kawashima I., Yoshida Y., Taya C., Shitara H., Yonekawa H., Karasuyama H., et al. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells. Int J Oncol 23 2 (2003) 381-388
12. Plautz G.E., Mukai S., Cohen P.A., and Shu S. Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors. J Immunol 165 7 (2000) 3656-3662
13. Ochsenbein A.F., and Zinkernagel R.M. Natural antibodies and complement link innate and acquired immunity. Immunol Today 21 12 (2000) 624-630
14. Youd M.E., Ferguson A.R., and Corley R.B. Synergistic roles of IgM and complement in antigen trapping and follicular localization. Eur J Immunol 32 8 (2002) 2328-2337
15. Alugupalli K.R., Leong J.M., Woodland R.T., Muramatsu M., Honjo T., and Gerstein R.M. B1b lymphocytes confer T cell-independent long-lasting immunity. Immunity 21 3 (2004) 379-390
16. Kieber-Emmons T, Luo P, Qiu J, Chang TY, O I, Blaszczyk-Thurin M, et al. Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses. Nat Biotech 1999; 17(7):660-65.
17. Monzavi-Karbassi B., Luo P., Jousheghany F., Torres-Quinones M., Cunto-Amesty G., Artaud C., et al. A Mimic of tumor rejection antigen-associated carbohydrates mediates an antitumor cellular response. Cancer Res 64 6 (2004) 2162-2166
18. Monzavi-Karbassi B., Artaud C., Jousheghany F., Hennings L., Carcel-Trullols J., Shaaf S., et al. Reduction of spontaneous metastases through induction of carbohydrate cross-reactive apoptotic antibodies. J Immunol 174 11 (2005) 7057-7065
19. Monzavi-Karbassi B., Shamloo S., Kieber-Emmons M., Jousheghany F., Luo P., Lin K.Y., et al. Priming characteristics of peptide mimotopes of carbohydrate antigens. Vaccine 21 7-8 (2003) 753-760
20. Monzavi-Karbassi B., Cunto-Amesty G., Luo P., Shamloo S., Blaszcyk-Thurin M., and Kieber-Emmons T. Immunization with a carbohydrate mimicking peptide augments tumor-specific cellular responses. Int Immunol 13 11 (2001) 1361-1371
21. Li G., Miles A., Line A., and Rees R.C. Identification of tumour antigens by serological analysis of cDNA expression cloning. Cancer Immunol Immunother 53 3 (2004) 139-143 Epub 2004 Jan 13
22. Suri A. Cancer testis antigens-their importance in immunotherapy and in the early detection of cancer. Expert Opin Biol Ther 6 4 (2006) 379-389
23. Waldmann T.A. Effective cancer therapy through immunomodulation. Annu Rev Med 57 (2006) 65-81
24. Radvanyi L. Discovery and immunologic validation of new antigens for therapeutic cancer vaccines. Int Arch Allergy Immunol 133 2 (2004) 179-197 Epub 2004 Feb 5
25. Hsueh E.C., Essner R., Foshag L.J., Ye W., and Morton D.L. Active immunotherapy by reinduction with a polyvalent allogeneic cell vaccine correlates with improved survival in recurrent metastatic melanoma. Ann Surg Oncol 9 5 (2002) 486-492
26. Slovin S.F., Ragupathi G., Fernandez C., Diani M., Jefferson M.P., Wilton A., et al. A polyvalent vaccine for high-risk prostate patients: "are more antigens better?". Cancer Immunol Immunother 56 12 (2007) 1921-1930 Epub 2007 Jul 10
27. Mariuzza R.A. Multiple paths to multispecificity. Immunity 24 4 (2006) 359-361
28. Janeway Jr. C.A., and Medzhitov R. Innate immune recognition. Annu Rev Immunol 20 (2002) 197-216
29. Rallabhandi P., Bell J., Boukhvalova M.S., Medvedev A., Lorenz E., Arditi M., et al. Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling. J Immunol 177 1 (2006) 322-332
30. Van Die I., Van Vliet S.J., Kwame Nyame A., Cummings R.D., Bank C.M., Appelmelk B., et al. The dendritic cell specific C-type lectin DC-SIGN is a receptor for Schistosoma mansoni egg antigens and recognizes the glycan antigen Lewis-x. Glycobiology 13 6 (2003) 471-478
31. Stebbing J., Savage P., Patterson S., and Gazzard B. All for CD91 and CD91 for all. J Antimicrob Chemother 53 1 (2004) 1-3
32. McFarland B.J., and Strong R.K. Thermodynamic analysis of degenerate recognition by the NKG2D immunoreceptor: not induced fit but rigid adaptation. Immunity 19 6 (2003) 803-812
33. Rousseau P.G., Mallett C.P., and Smith-Gill S.J. A substantial proportion of the adult BALB/c available B cell repertoire consists of multireactive B cells. Mol Immunol 26 10 (1989) 993-1006
34. Pashov A., Perry M., Dyar M., Chow M., and Kieber-Emmons T. Carbohydrate mimotopes in the rational design of cancer vaccines. Curr Top Med Chem 5 12 (2005) 1171-1185
35. Pashov A.D., Plaxco J., Kaveri S.V., Monzavi-Karbassi B., Harn D., and Kieber-Emmons T. Multiple antigenic mimotopes of HIV carbohydrate antigens-relating structure and antigenicity. J Biol Chem 9 (2006) 9
36. Harris S.L., Craig L., Mehroke J.S., Rashed M., Zwick M.B., Kenar K., et al. Exploring the basis of peptide-carbohydrate crossreactivity: evidence for discrimination by peptides between closely related anti-carbohydrate antibodies. Proc Natl Acad Sci USA 94 6 (1997) 2454-2459
37. Pashov A., Canziani G., Monzavi-Karbassi B., Kaveri S.V., Macleod S., Saha R., et al. Antigenic properties of peptide mimiotopes of HIV-1 associated carbohydrate antigens. J Biol Chem 14 (2005) 14
38. Pashov A., Monzavi-Karbassi B., Raghava G., and Kieber-Emmons T. Peptide mimotopes as prototypic templates of broad-spectrum surrogates of carbohydrate antigens for cancer vaccination. Crit Rev Immunol 27 3 (2007) 247-270
39. Monzavi-Karbassi B., Hennings L.J., Artaud C., Liu T., Jousheghany F., Pashov A., et al. Preclinical studies of carbohydrate mimetic peptide vaccines for breast cancer and melanoma. Vaccine 25 16 (2007) 3022-3031
40. Qiu J., Luo P., Wasmund K., Steplewski Z., and Kieber-Emmons T. Towards the development of peptide mimotopes of carbohydrate antigens as cancer vaccines. Hybridoma 18 1 (1999) 103-112
41. Wondimu A., Zhang T., Kieber-Emmons T., Gimotty P., Sproesser K., Somasundaram R., et al. Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Cancer Immunol Immunother 57 7 (2008) 1079-1089
42. Heath P.T., Booy R., Azzopardi H.J., Slack M.P., Bowen-Morris J., Griffiths H., et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. Jama 284 18 (2000) 2334-2340
43. Baumgarth N., Tung J.W., and Herzenberg L.A. Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion. Springer Semin Immunopathol 26 4 (2005) 347-362
44. WHO. Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Technical Report Series 2005; 927.
45. Lee Y.C., Kelly D.F., Yu L.M., Slack M.P., Booy R., Heath P.T., et al. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody. Clin Infect Dis 46 2 (2008) 186-192
46. Gulati U., Kumari K., Wu W., Keitel W.A., and Air G.M. Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination. Vaccine 23 11 (2005) 1414-1425
47. Hurwitz A.A., and Ji Q. Autoimmune depigmentation following sensitization to melanoma antigens. Methods Mol Med 102 (2004) 421-427
48. Galili U. The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. Immunol Cell Biol 83 6 (2005) 674-686
49. Preiss S., Kammertoens T., Lampert C., Willimsky G., and Blankenstein T. Tumor-induced antibodies resemble the response to tissue damage. Int J Cancer 115 3 (2005) 456-462
50. Pedersen N.C., and Morris B. The role of humoral antibody in the rejection of primary renal allografts in sheep. J Exp Med 140 3 (1974) 619-630
51. LaTemple D.C., Abrams J.T., Zhang S.Y., and Galili U. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1, 3 galactosyltransferase. Cancer Res 59 14 (1999) 3417-3423
52. Galili U. Immune response, accommodation, and tolerance to transplantation carbohydrate antigens. Transplantation 78 8 (2004) 1093-1098
53. Apostolopoulos V., Sandrin M.S., and McKenzie I.F. Mimics and cross reactions of relevance to tumour immunotherapy. Vaccine 18 3-4 (1999) 268-275
54. Apostolopoulos V., Osinski C., and McKenzie I.F. MUC1 cross-reactive Gal alpha(1,3)Gal antibodies in humans switch immune responses from cellular to humoral. Nat Med 4 3 (1998) 315-320
55. Valmori D., Souleimanian N.E., Tosello V., Bhardwaj N., Adams S., O'Neill D., et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 104 21 (2007) 8947-8952 Epub 2007 May 15
56. Guthmann M.D., Bitton R.J., Carnero A.J., Gabri M.R., Cinat G., Koliren L., et al. Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicity. J Immunother 27 6 (2004) 442-451
57. Krug L.M., Ragupathi G., Hood C., Kris M.G., Miller V.A., Allen J.R., et al. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin Cancer Res 10 18 Pt 1 (2004) 6094-6100
58. Ragupathi G., Koide F., Sathyan N., Kagan E., Spassova M., Bornmann W., et al. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers. Cancer Immunol Immunother 52 10 (2003) 608-616
59. Slovin S.F., Ragupathi G., Fernandez C., Jefferson M.P., Diani M., Wilton A.S., et al. A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21. Vaccine 23 24 (2005) 3114-3122
60. Sabbatini P.J., Kudryashov V., Ragupathi G., Danishefsky S.J., Livingston P.O., Bornmann W., et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial. Int J Cancer 87 1 (2000) 79-85
61. Holmberg L.A., and Sandmaier B.M. Vaccination with Theratope (STn-KLH) as treatment for breast cancer. Expert Rev Vaccines 3 6 (2004) 655-663
62. McCool T.L., Harding C.V., Greenspan N.S., and Schreiber J.R. B- and T-cell immune responses to pneumococcal conjugate vaccines: divergence between carrier- and polysaccharide-specific immunogenicity. Infect Immun 67 9 (1999) 4862-4869
63. Gilewski T., Ragupathi G., Bhuta S., Williams L.J., Musselli C., Zhang X.F., et al. Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial. Proc Natl Acad Sci USA 98 6 (2001) 3270-3275
64. Khan A.Q., Lees A., and Snapper C.M. Differential regulation of IgG anti-capsular polysaccharide and antiprotein responses to intact Streptococcus pneumoniae in the presence of cognate CD4+ T cell help. J Immunol 172 1 (2004) 532-539
65. Snapper C.M., Shen Y., Khan A.Q., Colino J., Zelazowski P., Mond J.J., et al. Distinct types of T-cell help for the induction of a humoral immune response to Streptococcus pneumoniae. Trends Immunol 22 6 (2001) 308-311
66. Mackay C.R. Immunological memory. Adv Immunol 53 (1993) 217-265
67. Martin F., and Kearney J.F. B-cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a "natural immune memory". Immunol Rev 175 (2000) 70-79
68. Tierens A., Delabie J., Michiels L., Vandenberghe P., and De Wolf-Peeters C. Marginal-zone B cells in the human lymph node and spleen show somatic hypermutations and display clonal expansion. Blood 93 1 (1999) 226-234
69. Klein U., Kuppers R., and Rajewsky K. Evidence for a large compartment of IgM-expressing memory B cells in humans. Blood 89 4 (1997) 1288-1298
70. Kruetzmann S., Rosado M.M., Weber H., Germing U., Tournilhac O., Peter H.H., et al. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med 197 7 (2003) 939-945
71. Weller S., Braun M.C., Tan B.K., Rosenwald A., Cordier C., Conley M.E., et al. Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood 104 12 (2004) 3647-3654 Epub 2004 Jun 10
72. Jackson L.A., Neuzil K.M., Yu O., Benson P., Barlow W.E., Adams A.L., et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 348 18 (2003) 1747-1755
73. Di Sabatino A., Rosado M.M., Ciccocioppo R., Cazzola P., Morera R., Corazza G.R., et al. Depletion of immunoglobulin M memory B cells is associated with splenic hypofunction in inflammatory bowel disease. Am J Gastroenterol 100 8 (2005) 1788-1795
74. Cunto-Amesty G., Luo P., Monzavi-Karbassi B., Lees A., and Kieber-Emmons T. Exploiting molecular mimicry to broaden the immune response to carbohydrate antigens for vaccine development. Vaccine 19 17-19 (2001) 2361-2368
75. Cornall R.J., and Goodnow C.C. B cell antigen receptor signalling in the balance of tolerance and immunity. Novartis Found Symp 215 (1998) 21-40
76. Wen L., Shinton S.A., Hardy R.R., and Hayakawa K. Association of B-1 B cells with follicular dendritic cells in spleen. J Immunol 174 11 (2005) 6918-6926
77. Pillai S., Cariappa A., and Moran S.T. Positive selection and lineage commitment during peripheral B-lymphocyte development. Immunol Rev 197 (2004) 206-218
78. Lopes-Carvalho T., and Kearney J.F. Development and selection of marginal zone B cells. Immunol Rev 197 (2004) 192-205
79. Martin F., and Kearney J. B1 cells: similarities and differences with other B cell subsets. Curr Opin Immunol 13 2 (2001) 195-201
80. Thurnheer M.C., Zuercher A.W., Cebra J.J., and Bos N.A. B1 cells contribute to serum IgM, but not to intestinal IgA, production in gnotobiotic Ig allotype chimeric mice. J Immunol 170 9 (2003) 4564-4571
81. Herzenberg L.A., and Tung J.W. B cell lineages: documented at last!. Nat Immunol 7 3 (2006) 225-226
82. Montecino-Rodriguez E., Leathers H., and Dorshkind K. Identification of a B-1 B cell-specified progenitor. Nat Immunol 7 3 (2006) 293-301
83. Haas K.M., Poe J.C., Steeber D.A., and Tedder T.F. B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity 23 1 (2005) 7-18
84. Dorshkind K., and Montecino-Rodriguez E. Fetal B-cell lymphopoiesis and the emergence of B-1-cell potential. Nat Rev Immunol 7 3 (2007) 213-219
85. Carey J.B., Moffatt-Blue C.S., Watson L.C., Gavin A.L., and Feeney A.J. Repertoire-based selection into the marginal zone compartment during B cell development. J Exp Med 205 9 (2008) 2043-2052
86. Fagarasan S., Watanabe N., and Honjo T. Generation, expansion, migration and activation of mouse B1 cells. Immunol Rev 176 (2000) 205-215
87. Martin F., Oliver A., and Kearney J. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity 14 5 (2001) 617-629
88. Kretschmer K., Jungebloud A., Stopkowicz J., Kleinke T., Hoffmann R., and Weiss S. The selection of marginal zone B cells differs from that of B-1a cells. J Immunol 171 12 (2003) 6495-6501
89. Kretschmer K., Jungebloud A., Stopkowicz J., Stoermann B., Hoffmann R., and Weiss S. Antibody repertoire and gene expression profile: implications for different developmental and functional traits of splenic and peritoneal B-1 lymphocytes. J Immunol 171 3 (2003) 1192-1201
90. Kretschmer K., Engel H., and Weiss S. Strong antigenic selection shaping the immunoglobulin heavy chain repertoire of B-1a lymphocytes in lambda 2(315) transgenic mice. Eur J Immunol 32 8 (2002) 2317-2327
91. Rajewsky K., Forster I., and Cumano A. Evolutionary and somatic selection of the antibody repertoire in the mouse. Science 238 4830 (1987) 1088-1094
92. Rowley B., Tang L., Shinton S., Hayakawa K., and Hardy R.R. Autoreactive B-1 B cells: constraints on natural autoantibody B cell antigen receptors. J Autoimmun 29 4 (2007) 236-245
93. Hardy R.R., Carmack C.E., Shinton S.A., Riblet R.J., and Hayakawa K. A single VH gene is utilized predominantly in anti-BrMRBC hybridomas derived from purified Ly-1 B cells. Definition of the VH11 family. J Immunol 142 10 (1989) 3643-3651
94. Kantor A.B., Merrill C.E., Herzenberg L.A., and Hillson J.L. An unbiased analysis of V(H)-D-J(H) sequences from B-1a, B-1b, and conventional B cells. J Immunol 158 3 (1997) 1175-1186
95. Wardemann H., Boehm T., Dear N., and Carsetti R. B-1a B cells that link the innate and adaptive immune responses are lacking in the absence of the spleen. J Exp Med 195 6 (2002) 771-780
96. Medzhitov R., and Janeway Jr. C.A. Decoding the patterns of self and nonself by the innate immune system. Science 296 5566 (2002) 298-300
97. Matzinger P. The danger model: a renewed sense of self. Science 296 5566 (2002) 301-305
98. Coutinho A. Will the idiotypic network help to solve natural tolerance?. Trends Immunol 24 2 (2003) 53-54
99. Burnet F.M. A modification of Jerne's theory of antibody production using the concept of clonal selection. CA: Cancer J Clin 26 2 (1976) 119-121
100. Kappler J.W., Roehm N., and Marrack P. T cell tolerance by clonal elimination in the thymus. Cell 49 2 (1987) 273-280
101. Weintraub A. Immunology of bacterial polysaccharide antigens. Carbohydr Res 338 23 (2003) 2539-2547
102. Vos Q., Lees A., Wu Z.Q., Snapper C.M., and Mond J.J. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev 176 12 (2000) 154-170
103. Ritter G., Fortunato S.R., Cohen L., Noguchi Y., Bernard E.M., Stockert E., et al. Induction of antibodies reactive with GM2 ganglioside after immunization with lipopolysaccharides from Camplyobacter jejuni. Int J Cancer 66 2 (1996) 184-190
104. Bowes T., Wagner E.R., Boffey J., Nicholl D., Cochrane L., Benboubetra M., et al. Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barre syndrome. Infect Immun 70 9 (2002) 5008-5018
105. Guttormsen H.K., Wetzler L.M., Finberg R.W., and Kasper D.L. Immunologic memory induced by a glycoconjugate vaccine in a murine adoptive lymphocyte transfer model. Infect Immun 66 5 (1998) 2026-2032
106. Guttormsen H.K., Sharpe A.H., Chandraker A.K., Brigtsen A.K., Sayegh M.H., and Kasper D.L. Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines. Infect Immun 67 12 (1999) 6375-6384
107. Tanemura M., Yin D., Chong A., and Galili U. Differential immune response to carbohydrate epitopes on allo- and xenografts: implications for accommodation. Transplant Proc 32 5 (2000) 991-993
108. Spalter S.H., Kaveri S.V., Bonnin E., Mani J.C., Cartron J.P., and Kazatchkine M.D. Normal human serum contains natural antibodies reactive with autologous ABO blood group antigens. Blood 93 12 (1999) 4418-4424
109. Vinuesa C.G., and MacLennan I.C. Antibody responses to polysaccharides. In: Wong S.Y.C., and Arsequell G. (Eds). Immunobiology of carbohydrates (2003), Springer, New York, US 128-147
110. Gonzalez-Fernandez A., Faro J., and Fernandez C. Immune responses to polysaccharides: lessons from humans and mice. Vaccine 26 3 (2008) 292-300
111. Vollmers H.P., and Brandlein S. Nature's best weapons to fight cancer. Revival of human monoclonal IgM antibodies. Hum Antibodies 11 4 (2002) 131-142
112. Muller S., and Hanisch F.G. Recombinant MUC1 probe authentically reflects cell-specific O-glycosylation profiles of endogenous breast cancer mucin. High density and prevalent core 2-based glycosylation. J Biol Chem 277 29 (2002) 26103-26112
113. Inoue M., Takahashi S., Yamashina I., Kaibori M., Okumura T., Kamiyama Y., et al. High density O-glycosylation of the MUC2 tandem repeat unit by N-acetylgalactosaminyltransferase-3 in colonic adenocarcinoma extracts. Cancer Res 61 3 (2001) 950-956
114. Wondimu A., Zhang T., Kieber-Emmons T., Gimotty P., Sproesser K., Somasundaram R., et al. Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Cancer Immunol Immunother 57 7 (2007) 1079-1089
115. Zimecki M., and Kapp J.A. Presentation of antigen by B cell subsets. II. The role of CD5 B cells in the presentation of antigen to antigen-specific T cells. Arch Immunol Ther Exp (Warsz) 42 5-6 (1994) 349-353
116. Bamba H., Ishigaki H., Ishida H., Kajino K., Fujiyama Y., and Ogasawara K. B1-B cells are the main antigen presenting cells in CpG-ODN-stimulated peritoneal exudate cells. Microbiol Immunol 49 1 (2005) 89-95
117. Lopes-Carvalho T., Foote J., and Kearney J.F. Marginal zone B cells in lymphocyte activation and regulation. Curr Opin Immunol 17 3 (2005) 244-250
118. Zhong X., Gao W., Degauque N., Bai C., Lu Y., Kenny J., et al. Reciprocal generation of Th1/Th17 and T(reg) cells by B1 and B2 B cells. Eur J Immunol 37 9 (2007) 2400-2404
119. Harbers S.O., Crocker A., Catalano G., D'Agati V., Jung S., Desai D.D., et al. Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance. J Clin Invest 117 5 (2007) 1361-1369
120. Desai D.D., Harbers S.O., Flores M., Colonna L., Downie M.P., Bergtold A., et al. Fc gamma receptor IIB on dendritic cells enforces peripheral tolerance by inhibiting effector T cell responses. J Immunol 178 10 (2007) 6217-6226
121. Hart B.A., and van Kooyk Y. Yin-Yang regulation of autoimmunity by DCs. Trends Immunol 25 7 (2004) 353-359
122. Talmadge J.E., Meyers K.M., Prieur D.J., and Starkey J.R. Role of NK cells in tumour growth and metastasis in beige mice. Nature 284 5757 (1980) 622-624
123. Gorelik E., Wiltrout R.H., Okumura K., Habu S., and Herberman R.B. Role of NK cells in the control of metastatic spread and growth of tumor cells in mice. Int J Cancer 30 1 (1982) 107-112
124. Vos Q., Snapper C.M., and Mond J.J. Heterogeneity in the ability of cytotoxic murine NK cell clones to enhance Ig secretion in vitro. Int Immunol 11 2 (1999) 159-168
125. Snapper C.M., Yamaguchi H., Moorman M.A., and Mond J.J. An in vitro model for T cell-independent induction of humoral immunity. A requirement for NK cells. J Immunol 152 10 (1994) 4884-4892
126. Kelly J.M., Darcy P.K., Markby J.L., Godfrey D.I., Takeda K., Yagita H., et al. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol 3 1 (2002) 83-90
127. Geldhof A.B., Van Ginderachter J.A., Liu Y., Noel W., Raes G., and De Baetselier P. Antagonistic effect of NK cells on alternatively activated monocytes: a contribution of NK cells to CTL generation. Blood 100 12 (2002) 4049-4058
128. Adam C., King S., Allgeier T., Braumuller H., Luking C., Mysliwietz J., et al. DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. Blood 106 1 (2005) 338-344
129. Yu Z., Maoui M., Wu L., Banville D., and Shen S. mSiglec-E, a novel mouse CD33-related siglec (sialic acid-binding immunoglobulin-like lectin) that recruits Src homology 2 (SH2)-domain-containing protein tyrosine phosphatases SHP-1 and SHP-2. Biochem J 353 Pt 3 (2001) 483-492
130. Zhang J.Q., Biedermann B., Nitschke L., and Crocker P.R. The murine inhibitory receptor mSiglec-E is expressed broadly on cells of the innate immune system whereas mSiglec-F is restricted to eosinophils. Eur J Immunol 34 4 (2004) 1175-1184
131. O'Garra A., Chang R., Go N., Hastings R., Haughton G., and Howard M. Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10. Eur J Immunol 22 3 (1992) 711-717
132. O'Garra A., and Howard M. Cytokines and Ly-1 (B1) B cells. Int Rev Immunol 8 2-3 (1992) 219-234
133. Mocellin S., Panelli M.C., Wang E., Nagorsen D., and Marincola F.M. The dual role of IL-10. Trends Immunol 24 1 (2003) 36-43
134. Mocellin S., Panelli M., Wang E., Rossi C.R., Pilati P., Nitti D., et al. IL-10 stimulatory effects on human NK cells explored by gene profile analysis. Genes Immun 5 8 (2004) 621-630
135. Petersson M., Charo J., Salazar-Onfray F., Noffz G., Mohaupt M., Qin Z., et al. Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J Immunol 161 5 (1998) 2099-2105
136. Alugupalli K.R., Gerstein R.M., Chen J., Szomolanyi-Tsuda E., Woodland R.T., and Leong J.M. The resolution of relapsing fever borreliosis requires IgM and is concurrent with expansion of B1b lymphocytes. J Immunol 170 7 (2003) 3819-3827
137. Monzavi-Karbassi B., Cunto-Amesty G., Luo P., Lees A., and Kieber-Emmons T. Immunological characterization of peptide mimetics of carbohydrate antigens in vaccine design strategies. Biologicals 29 3-4 (2001) 249-257
138. Snapper C.M., Rosas F., Moorman M.A., Jin L., Shanebeck K., Klinman D.M., et al. IFN-gamma is a potent inducer of Ig secretion by sort-purified murine B cells activated through the mIg, but not the CD40, signaling pathway. Int Immunol 8 6 (1996) 877-885
139. Yi A.K., Chace J.H., Cowdery J.S., and Krieg A.M. IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. J Immunol 156 2 (1996) 558-564
140. Pflumio F., Fonteneau P., and Loor F. Impaired antibody response of C57BL/6 beige mutant mice to a thymus-independent type 2 antigen. Immunol Lett 23 4 (1990) 269-274
141. Michael A., Hackett J.J., Bennett M., Kumar V., and Yuan D. Regulation of B lymphocytes by natural killer cells. Role of IFN-gamma. J Immunol 142 4 (1989) 1095-1101
142. Attanavanich K., and Kearney J.F. Marginal zone, but not follicular B cells, are potent activators of naive CD4 T cells. J Immunol 172 2 (2004) 803-811
143. Li S., Yan Y., Lin Y., Bullens D.M., Rutgeerts O., Goebels J., et al. Rapidly induced T-cell independent xenoantibody production is mediated by marginal zone B cells and requires help from NK cells. Blood 110 12 (2007) 3926-3935
144. Jeurissen A., Billiau A.D., Moens L., Shengqiao L., Landuyt W., Wuyts G., et al. CD4+ T lymphocytes expressing CD40 ligand help the IgM antibody response to soluble pneumococcal polysaccharides via an intermediate cell type. J Immunol 176 1 (2006) 529-536
145. Wang C., Khalil M., Ravetch J., and Diamond B. The naive B cell repertoire predisposes to antigen-induced systemic Lupus Erythematosus. J Immunol 170 9 (2003) 4826-4832